Core Insights - PharmAla Biotech Holdings Inc. has successfully completed the release testing of its first Australian-made batch of LaNeo™ MDMA 40mg capsules, marking a significant milestone for the company [1] - The company is set to enter an active production schedule for 2026, which includes the development of 20mg capsules and the manufacture of ALA-002 capsules [2] - PharmAla has completed its first delivery of Australian-made product to the Orygen Institute, supporting a Phase 3 Trial for social anxiety in autistic youth, concluding its contract with Orygen [3] Company Overview - PharmAla Biotech Holdings Inc. focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the global backlog of clinical-grade MDMA for clinical trials and commercial sales [4] - The company is recognized as the only provider of clinical-grade MDMA for patient treatments outside of clinical trials and has completed proof-of-concept research into several drug candidates, including ALA-002 [4] - PharmAla operates under a "regulatory first" principle, emphasizing the importance of strong relationships with regulators in the psychedelics industry [4]